Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.52 |
| ▸ | RARA | P10276 | 2/20 | 0.44 |
| ▸ | RARB | P10826 | 2/20 | 0.44 |
| ▸ | RARG | P13631 | 2/20 | 0.44 |
| ▸ | HNF4A | P41235 | 3/20 | 0.43 |
| ▸ | RXRB | P28702 | 4/20 | 0.43 |
| ▸ | RXRG | P48443 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960820 | 1.00 | RXRA (0.52) | RXRARARARARBRARGHNF4A | |
| SCHEMBL6688833 | 0.87 | RXRA (0.40) | RXRARARARARBRARGHNF4A | |
| SCHEMBL8458065 | 0.87 | RXRA (0.40) | RXRARARARARBRARGHNF4A | |
| SCHEMBL8458070 | 0.87 | RXRA (0.40) | RXRARARARARBRARGHNF4A | |
| SCHEMBL4959128 | 0.85 | RXRA (0.67) | RXRARARARARBRARGHNF4A | |
| SCHEMBL8462265 | 0.84 | RXRA (0.45) | RXRARARARARBRARGHNF4A | |
| SCHEMBL6675620 | 0.83 | RXRA (0.65) | RXRARARARARBRARGHNF4A | |
| SCHEMBL4959698 | 0.81 | RXRA (0.55) | RXRARARARARBRARGHNF4A | |
| SCHEMBL6673775 | 0.81 | RXRA (0.57) | RXRARARARARBRARGHNF4A | |
| SCHEMBL6676520 | 0.80 | RXRA (0.56) | RXRARARARARBRARGHNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930005-A1 | Stabilized formulation of selective ligands of retinoic acid gamma-receptors | Johnson and Johnson Consumer Companies, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1351685-B1 | STABILIZED FORMULATION OF SELECTIVE LIGANDS OF RETINOIC ACID GAMMA-RECEPTORS | JOHNSON & JOHNSON CONSUMER (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20050059707-A1 | Stabilization of retinoid compounds | RAO CHAKRADHARA S (US) | 2005-03-17 | — | — | US | disclosed |
| US-6844364-B2 | Stabilization of retinoid compounds | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| EP-0862554-B1 | AROMATIC CARBOXYLIC ACID ESTERS, THE PRODUCTION OF SAME AND USE OF SAME AS MEDICAMENTS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| EP-1351685-A2 | STABILIZED FORMULATION OF SELECTIVE LIGANDS OF RETINOIC ACID GAMMA-RECEPTORS | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030032659-A1 | Stabilization of retinoid compounds | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-02-13 | — | — | US | disclosed |
| WO-2002074310-A2 | STABILIZED FORMULATION OF SELECTIVE LIGANDS OF RETINOIC ACID GAMMA-RECEPTORS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-5958956-A | SKIN DISORDERS; WOUND HEALING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0862554-A1 | AROMATIC CARBOXYLIC ACID ESTERS, THE PRODUCTION OF SAME AND USE OF SAME AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-09 | — | — | EP | disclosed |
| US-5726191-A | TREATEMENT OF LIGHT AND AGE DAMAGED SKIN | HOFFMANN-LA ROCHE INC. (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1997018192-A1 | AROMATIC CARBOXYLIC ACID ESTERS, THE PRODUCTION OF SAME AND USE OF SAME AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059707-A1 | Stabilization of retinoid compounds | STRA6, RXRA, RARA | RXRA 2/4885RARA 3/4885RARB 9/4885 |
| US-20030032659-A1 | Stabilization of retinoid compounds | RXRA, RARA, RXRB | RXRA 1/4885RARA 2/4885RARB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.